TXG
10x Genomics, Inc. · Healthcare · Medical - Healthcare Information Services
Señales de momentum (gestores comparables):
amplitud de titulares +7.1% ·
flujo de acciones +1.4% ·
nuevas posiciones netas +6.7%
— fórmula
Acumulación amplia — aumento de acciones entre más titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q4 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 114 | +7 | 98.90M | $3.78B | +16 | −8 |
| Q1 2026 | 109 | +3 | 94.02M | $1.99B | +12 | −10 |
| Q4 2025 | 107 | +3 | 97.86M | $1.59B | +4 | — |
| Q3 2025 | 19 | -2 | 71.88M | $839.83M | — | −3 |
| Q2 2025 | 19 | +1 | 64.66M | $748.72M | +2 | −1 |
| Q1 2025 | 15 | 0 | 30.56M | $266.82M | +1 | −1 |
| Q4 2024 | 15 | +1 | 24.83M | $356.61M | +3 | −2 |
| Q3 2024 | 13 | 0 | 22.71M | $512.82M | +1 | −1 |
| Q2 2024 | 13 | — | 21.07M | $409.76M | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 11.94M | +11.1% | $171.52M | 1.4% | ▲ Add | 3 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 2.01M | -27.8% | $28.81M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 2.01M | -27.8% | $28.81M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (pasivo) | 1.81M | -0.1% | $26.07M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (pasivo) | 1.81M | -0.1% | $26.07M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 1.78M | -29.2% | $25.58M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 1.78M | -29.2% | $25.58M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | State Street Global Advisors ✦ (pasivo) | 1.77M | — | $25.49M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 1.32M | +291.2% | $18.95M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 1.22M | Nuevo | $17.50M | 0.0% | New | 1 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 1.22M | Nuevo | $17.50M | 0.0% | New | 1 | SEC ↗ |
| 12 | Millennium Management ✦ | 991.16K | +7.9% | $14.23M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | Capital World Investors ✦ | 793.30K | 0.0% | $11.39M | 0.0% | Held | 3 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 517.20K | -29.1% | $7.43M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 517.20K | -29.1% | $7.43M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 517.20K | -29.1% | $7.43M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 517.20K | -29.1% | $7.43M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | Renaissance Technologies ✦ | 386.95K | Nuevo | $5.56M | 0.0% | New | 1 | SEC ↗ |
| 19 | PRIMECAP Management ✦ | 127.60K | -56.8% | $1.83M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 20 | Norges Bank ✦ (pasivo) | 91.58K | +123.0% | $1.32M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 21 | Marshall Wace ✦ | 46.86K | -90.0% | $672,924 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 22 | Marshall Wace ✦ | 46.86K | -90.0% | $672,924 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 23 | Gotham Asset Management ✦ | 18.39K | Nuevo | $264,066 | 0.0% | New | 1 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| D. E. Shaw & Co. | $17.50M | 0.0% |
| D. E. Shaw & Co. | $17.50M | 0.0% |
| Renaissance Technologies | $5.56M | 0.0% |
| Gotham Asset Management | $264,066 | 0.0% |
Posición cerrada
| Point72 Asset Management | $27.78M | era 0.1% |
| Baillie Gifford | $911,736 | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 328 tenedores, 124.40M acciones, $2.59B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Director · 2.27K acc. · $129,902
Director · 5.28K acc. · $302,377
Director · 17.00K acc. · $978,880
Director · 3.00K acc. · $176,175
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología